Literature DB >> 11971096

Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children.

G F A Harding1, E L Spencer, J M Wild, M Conway, R L Bohn.   

Abstract

OBJECTIVE: To derive a visual-evoked potential (VEP) technique for identifying visual field defects in children with epilepsy treated with vigabatrin and unable to perform perimetry.
BACKGROUND: Studies have linked vigabatrin to a specific pattern of visual field loss. Few studies have included the pediatric population because of difficulties in assessing the visual field by perimetry below a developmental age of 9 years.
METHODS: A field-specific VEP was developed with a central (0 degrees to 5 degrees radius) and peripheral stimulus (30 degrees to 60 degrees radius). Stimuli consisted of black and white checks that increased in size with eccentricity. Checks reversed at different rates, allowing separate central and peripheral responses to be recorded. Five vigabatrin-treated young adults with field defects were identified using this stimulus. Electroretinograms (ERG) were recorded to examine the effects of vigabatrin on retinal function. Thirty-nine children aged 3 to 15 years were included in the study. Twelve patients were examined by both the field-specific stimulus test and perimetry. The diagnostic performance of the field-specific stimulus test was compared with that of perimetry.
RESULTS: Thirty-five of 39 children complied with the field-specific stimulus, 26 of 39 complied with the ERG, and 12 of 39 complied with perimetry. Using the summed amplitude of the peripheral response from O(2) and O(1), responses below 10 microV were deemed abnormal. The field-specific stimulus identified 3 of 4 abnormal perimetry results and 7 of 8 normal perimetry results, giving a sensitivity of 75% and a specificity of 87.5%. When comparing perimetry results with the ERG parameters, only the 30-Hz flicker amplitude, with a cutoff below 70 microV, gave a useful indication of visual field loss.
CONCLUSION: Field-specific VEP are well tolerated by children older than 2 years of age and are sensitive and specific in identifying vigabatrin-associated peripheral field defects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11971096     DOI: 10.1212/wnl.58.8.1261

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  Effect of different stimulus configurations on the visual evoked potential (VEP).

Authors:  Naveen K Yadav; Diana P Ludlam; Kenneth J Ciuffreda
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

Review 2.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

3.  Central and peripheral steady-state visual evoked potentials in children with optic pathway gliomas.

Authors:  Sarah Zakaib Rassi; Luis H Ospina; Ariane Bochereau; Yvan Samson; Sébastien Perreault; Dave Saint-Amour
Journal:  Doc Ophthalmol       Date:  2019-06-26       Impact factor: 2.379

4.  Visual Evoked Potentials as a Readout of Cortical Function in Infants With Tuberous Sclerosis Complex.

Authors:  Kandice J Varcin; Charles A Nelson; Jordan Ko; Mustafa Sahin; Joyce Y Wu; Shafali Spurling Jeste
Journal:  J Child Neurol       Date:  2015-05-26       Impact factor: 1.987

5.  A frequency-tagging electrophysiological method to identify central and peripheral visual field deficits.

Authors:  Noémie Hébert-Lalonde; Lionel Carmant; Dima Safi; Marie-Sylvie Roy; Maryse Lassonde; Dave Saint-Amour
Journal:  Doc Ophthalmol       Date:  2014-05-10       Impact factor: 2.379

6.  Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.

Authors:  J Raymond Buncic; Carol A Westall; Carole M Panton; J Robert Munn; Leslie D MacKeen; William J Logan
Journal:  Ophthalmology       Date:  2004-10       Impact factor: 12.079

7.  Changes in the electroretinogram resulting from discontinuation of vigabatrin in children.

Authors:  Carol A Westall; Rita Nobile; Sharon Morong; J Raymond Buncic; William J Logan; Carole M Panton
Journal:  Doc Ophthalmol       Date:  2003-11       Impact factor: 2.379

8.  Examining visual field defects in the paediatric population exposed to vigabatrin.

Authors:  E L Spencer; G F A Harding
Journal:  Doc Ophthalmol       Date:  2003-11       Impact factor: 2.379

9.  Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study.

Authors:  Carol A Westall; Tom Wright; Filomeno Cortese; Ananthavalli Kumarappah; O Carter Snead; Joseph R Buncic
Journal:  Neurology       Date:  2014-11-07       Impact factor: 9.910

10.  Treatment of refractory complex partial seizures: role of vigabatrin.

Authors:  Elizabeth J Waterhouse; Kimberly N Mims; Soundarya N Gowda
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.